Drug Pipeline

DZD6008 Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
3
Active Studies
3
Recruiting
2
Top Sponsors
2
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-05-27 NCT07079475
Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have…		 Enrollment reduced: 200 -> 160 participants
2026-05-27 NCT07079475
Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have…		 Trial sites expanded: 7 -> 17 locations
Active Studies by Phase
Phase 1/2
1
Phase 1
2
Active Trials
NCT IDTitleConditionStatus
Phase 1/2
NCT07079475 Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have… Non-Small Cell Lung Cancer Recruiting
Phase 1
NCT06813365 Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR… Nonsmall-cell Lung Cancer Recruiting
NCT06905197 A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have… Non Small Cell Lung Cancer Recruiting
Sponsors Running DZD6008 Trials
Dizal Pharmaceuticals (2) Dizal (Jiangsu) Pharmaceutical Co., Ltd. (1)
Disease Areas
Lung Cancer (3) Non-Small Cell Lung Cancer (NSCLC) (2)
Get alerts when DZD6008 trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free